Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 180

1.

Effect of food on the bioavailability and tolerability of the JAK2-selective inhibitor fedratinib (SAR302503): Results from two phase I studies in healthy volunteers.

Zhang M, Xu C, Ma L, Shamiyeh E, Yin J, von Moltke LL, Smith WB.

Clin Pharmacol Drug Dev. 2015 Jul;4(4):315-21. doi: 10.1002/cpdd.161. Epub 2014 Oct 27.

PMID:
27136912
2.

Lack of clinical pharmacodynamic and pharmacokinetic drug-drug interactions between warfarin and the antisense oligonucleotide mipomersen.

Li Z, Hard ML, Grundy JS, Singh T, von Moltke LL, Boltje I.

J Cardiovasc Pharmacol. 2014 Aug;64(2):164-71. doi: 10.1097/FJC.0000000000000101.

PMID:
24691275
3.

Pharmacokinetics, safety and tolerability of mipomersen in healthy Japanese volunteers and comparison with Western subjects.

Li Z, Hard ML, Andersen G, Pabst G, Wagener G, Singh T, Chin W, Culm-Merdek K, Boltje I, von Moltke LL.

Int J Clin Pharmacol Ther. 2014 Apr;52(4):314-20. doi: 10.5414/CP201975.

PMID:
24548981
4.

A randomized, placebo-controlled study of the pharmacokinetics, pharmacodynamics, and tolerability of the oral JAK2 inhibitor fedratinib (SAR302503) in healthy volunteers.

Zhang M, Xu CR, Shamiyeh E, Liu F, Yin JY, von Moltke LL, Smith WB.

J Clin Pharmacol. 2014 Apr;54(4):415-21. doi: 10.1002/jcph.218. Epub 2013 Nov 16.

PMID:
24165976
5.

Mechanism of cytochrome P450-3A inhibition by ketoconazole.

Greenblatt DJ, Zhao Y, Venkatakrishnan K, Duan SX, Harmatz JS, Parent SJ, Court MH, von Moltke LL.

J Pharm Pharmacol. 2011 Feb;63(2):214-21. doi: 10.1111/j.2042-7158.2010.01202.x.

PMID:
21235585
6.

A quantitative framework and strategies for management and evaluation of metabolic drug-drug interactions in oncology drug development: new molecular entities as object drugs.

Venkatakrishnan K, Pickard MD, von Moltke LL.

Clin Pharmacokinet. 2010 Nov;49(11):703-27. doi: 10.2165/11536740-000000000-00000.

PMID:
20923246
7.

Sources of variability in ketoconazole inhibition of human cytochrome P450 3A in vitro.

Greenblatt DJ, Venkatakrishnan K, Harmatz JS, Parent SJ, von Moltke LL.

Xenobiotica. 2010 Oct;40(10):713-20. doi: 10.3109/00498254.2010.506224. Review.

PMID:
20712450
8.

Pharmacokinetic and pharmacodynamic study of two doses of bortezomib in patients with relapsed multiple myeloma.

Reece DE, Sullivan D, Lonial S, Mohrbacher AF, Chatta G, Shustik C, Burris H 3rd, Venkatakrishnan K, Neuwirth R, Riordan WJ, Karol M, von Moltke LL, Acharya M, Zannikos P, Keith Stewart A.

Cancer Chemother Pharmacol. 2011 Jan;67(1):57-67. doi: 10.1007/s00280-010-1283-3. Epub 2010 Mar 20.

9.
10.

Quantitative prediction and clinical observation of a CYP3A inhibitor-based drug-drug interactions with MLN3897, a potent C-C chemokine receptor-1 antagonist.

Lu C, Balani SK, Qian MG, Prakash SR, Ducray PS, von Moltke LL.

J Pharmacol Exp Ther. 2010 Feb;332(2):562-8. doi: 10.1124/jpet.109.161893. Epub 2009 Nov 4.

PMID:
19889796
11.

Short-term clarithromycin administration impairs clearance and enhances pharmacodynamic effects of trazodone but not of zolpidem.

Farkas D, Volak LP, Harmatz JS, von Moltke LL, Court MH, Greenblatt DJ.

Clin Pharmacol Ther. 2009 Jun;85(6):644-50. doi: 10.1038/clpt.2008.293. Epub 2009 Feb 25.

PMID:
19242403
12.

Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis.

Knox TA, Oleson L, von Moltke LL, Kaufman RC, Wanke CA, Greenblatt DJ.

J Acquir Immune Defic Syndr. 2008 Dec 1;49(4):358-68.

PMID:
19186349
13.

Role of NADPH-cytochrome P450 reductase and cytochrome-b5/NADH-b5 reductase in variability of CYP3A activity in human liver microsomes.

Gan L, von Moltke LL, Trepanier LA, Harmatz JS, Greenblatt DJ, Court MH.

Drug Metab Dispos. 2009 Jan;37(1):90-6. doi: 10.1124/dmd.108.023424. Epub 2008 Oct 6.

14.

Gender has a small but statistically significant effect on clearance of CYP3A substrate drugs.

Greenblatt DJ, von Moltke LL.

J Clin Pharmacol. 2008 Nov;48(11):1350-5. doi: 10.1177/0091270008323754. Epub 2008 Aug 29. Review.

PMID:
18757784
15.

Predicting interactions between conventional medications and botanical products on the basis of in vitro investigations.

Markowitz JS, von Moltke LL, Donovan JL.

Mol Nutr Food Res. 2008 Jul;52(7):747-54. doi: 10.1002/mnfr.200700159. Review.

PMID:
18324706
16.

Induction of P-glycoprotein expression and activity by ritonavir in bovine brain microvessel endothelial cells.

Perloff MD, von Moltke LL, Fahey JM, Greenblatt DJ.

J Pharm Pharmacol. 2007 Jul;59(7):947-53.

PMID:
17637189
17.

Pharmacokinetic and pharmacodynamic interactions between zolpidem and caffeine.

Cysneiros RM, Farkas D, Harmatz JS, von Moltke LL, Greenblatt DJ.

Clin Pharmacol Ther. 2007 Jul;82(1):54-62. Epub 2007 Apr 18.

PMID:
17443132
18.

Role of CYP3A and CYP2E1 in alcohol-mediated increases in acetaminophen hepatotoxicity: comparison of wild-type and Cyp2e1(-/-) mice.

Wolf KK, Wood SG, Allard JL, Hunt JA, Gorman N, Walton-Strong BW, Szakacs JG, Duan SX, Hao Q, Court MH, von Moltke LL, Greenblatt DJ, Kostrubsky V, Jeffery EH, Wrighton SA, Gonzalez FJ, Sinclair PR, Sinclair JF.

Drug Metab Dispos. 2007 Jul;35(7):1223-31. Epub 2007 Mar 28.

PMID:
17392391
19.

Human pregnane X receptor: genetic polymorphisms, alternative mRNA splice variants, and cytochrome P450 3A metabolic activity.

He P, Court MH, Greenblatt DJ, von Moltke LL.

J Clin Pharmacol. 2006 Nov;46(11):1356-69.

PMID:
17050801
20.

Factors influencing midazolam hydroxylation activity in human liver microsomes.

He P, Court MH, Greenblatt DJ, von Moltke LL.

Drug Metab Dispos. 2006 Jul;34(7):1198-207. Epub 2006 Apr 25.

PMID:
16638818
21.

Ritonavir has minimal impact on the pharmacokinetic disposition of a single dose of bupropion administered to human volunteers.

Hesse LM, Greenblatt DJ, von Moltke LL, Court MH.

J Clin Pharmacol. 2006 May;46(5):567-76.

PMID:
16638740
22.

The novel UGT1A9 intronic I399 polymorphism appears as a predictor of 7-ethyl-10-hydroxycamptothecin glucuronidation levels in the liver.

Girard H, Villeneuve L, Court MH, Fortier LC, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, Guillemette C.

Drug Metab Dispos. 2006 Jul;34(7):1220-8. Epub 2006 Apr 4.

PMID:
16595709
23.

Apparent active transport of MDMA is not mediated by P-glycoprotein: a comparison with MDCK and Caco-2 monolayers.

Bertelsen KM, Greenblatt DJ, von Moltke LL.

Biopharm Drug Dispos. 2006 Jul;27(5):219-27.

PMID:
16552717
24.

Effect of extended exposure to grapefruit juice on cytochrome P450 3A activity in humans: comparison with ritonavir.

Culm-Merdek KE, von Moltke LL, Gan L, Horan KA, Reynolds R, Harmatz JS, Court MH, Greenblatt DJ.

Clin Pharmacol Ther. 2006 Mar;79(3):243-54. Epub 2006 Feb 7.

PMID:
16513448
25.

In vitro interactions of water-soluble garlic components with human cytochromes p450.

Greenblatt DJ, Leigh-Pemberton RA, von Moltke LL.

J Nutr. 2006 Mar;136(3 Suppl):806S-809S. doi: 10.1093/jn/136.3.806S.

PMID:
16484569
26.

Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate.

Greenblatt DJ, von Moltke LL, Luo Y, Perloff ES, Horan KA, Bruce A, Reynolds RC, Harmatz JS, Avula B, Khan IA, Goldman P.

J Clin Pharmacol. 2006 Feb;46(2):214-21.

PMID:
16432273
27.

Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies.

Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA.

Clin Pharmacol Ther. 2006 Jan;79(1):125-33.

PMID:
16413247
28.

Fluvoxamine impairs single-dose caffeine clearance without altering caffeine pharmacodynamics.

Culm-Merdek KE, von Moltke LL, Harmatz JS, Greenblatt DJ.

Br J Clin Pharmacol. 2005 Nov;60(5):486-93.

29.

Role of the nuclear receptor pregnane X receptor in acetaminophen hepatotoxicity.

Wolf KK, Wood SG, Hunt JA, Walton-Strong BW, Yasuda K, Lan L, Duan SX, Hao Q, Wrighton SA, Jeffery EH, Evans RM, Szakacs JG, von Moltke LL, Greenblatt DJ, Court MH, Schuetz EG, Sinclair PR, Sinclair JF.

Drug Metab Dispos. 2005 Dec;33(12):1827-36. Epub 2005 Sep 1.

PMID:
16141365
30.

UGT1A1 polymorphisms are important determinants of dietary carcinogen detoxification in the liver.

Girard H, Thibaudeau J, Court MH, Fortier LC, Villeneuve L, Caron P, Hao Q, von Moltke LL, Greenblatt DJ, Guillemette C.

Hepatology. 2005 Aug;42(2):448-57.

PMID:
15986396
31.

Genotype-phenotype associations of cytochrome P450 3A4 and 3A5 polymorphism with midazolam clearance in vivo.

He P, Court MH, Greenblatt DJ, Von Moltke LL.

Clin Pharmacol Ther. 2005 May;77(5):373-87.

PMID:
15900284
32.

Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro.

Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ, von Moltke LL.

Drug Metab Dispos. 2005 Jun;33(6):764-70. Epub 2005 Mar 11.

PMID:
15764714
33.

UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: I. Identification of polymorphisms in the 5'-regulatory and exon 1 regions, and association with human liver UGT1A6 gene expression and glucuronidation.

Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, Court MH.

J Pharmacol Exp Ther. 2005 Jun;313(3):1331-9. Epub 2005 Mar 10.

PMID:
15761114
34.

UDP glucuronosyltransferase (UGT) 1A6 pharmacogenetics: II. Functional impact of the three most common nonsynonymous UGT1A6 polymorphisms (S7A, T181A, and R184S).

Krishnaswamy S, Hao Q, Al-Rohaimi A, Hesse LM, von Moltke LL, Greenblatt DJ, Court MH.

J Pharmacol Exp Ther. 2005 Jun;313(3):1340-6. Epub 2005 Mar 10.

PMID:
15761113
35.

Interaction of warfarin with drugs, natural substances, and foods.

Greenblatt DJ, von Moltke LL.

J Clin Pharmacol. 2005 Feb;45(2):127-32. Review.

PMID:
15647404
36.

The influence of age and sex on the clearance of cytochrome P450 3A substrates.

Cotreau MM, von Moltke LL, Greenblatt DJ.

Clin Pharmacokinet. 2005;44(1):33-60. Review.

PMID:
15634031
37.

Age and gender effects on the pharmacokinetics and pharmacodynamics of triazolam, a cytochrome P450 3A substrate.

Greenblatt DJ, Harmatz JS, von Moltke LL, Wright CE, Shader RI.

Clin Pharmacol Ther. 2004 Nov;76(5):467-79.

PMID:
15536461
38.

Interactions of tamoxifen, N-desmethyltamoxifen and 4-hydroxytamoxifen with P-glycoprotein and CYP3A.

Bekaii-Saab TS, Perloff MD, Weemhoff JL, Greenblatt DJ, von Moltke LL.

Biopharm Drug Dispos. 2004 Oct;25(7):283-9.

PMID:
15386482
39.

Role of CYP3A enzymes in the biotransformation of triazolam in rat liver.

Warrington JS, Greenblatt DJ, Von Moltke LL.

Xenobiotica. 2004 May;34(5):463-71.

PMID:
15370962
40.

Inhibition of human cytochromes P450 by components of Ginkgo biloba.

von Moltke LL, Weemhoff JL, Bedir E, Khan IA, Harmatz JS, Goldman P, Greenblatt DJ.

J Pharm Pharmacol. 2004 Aug;56(8):1039-44.

PMID:
15285849
41.

Ethanol inhibits in-vitro metabolism of nifedipine, triazolam and testosterone in human liver microsomes.

Patki KC, Greenblatt DJ, von Moltke LL.

J Pharm Pharmacol. 2004 Aug;56(8):963-6.

PMID:
15285839
42.

Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver.

Girard H, Court MH, Bernard O, Fortier LC, Villeneuve L, Hao Q, Greenblatt DJ, von Moltke LL, Perussed L, Guillemette C.

Pharmacogenetics. 2004 Aug;14(8):501-15.

PMID:
15284532
43.

Evaluation of 5-hydroxytryptophol and other endogenous serotonin (5-hydroxytryptamine) analogs as substrates for UDP-glucuronosyltransferase 1A6.

Krishnaswamy S, Hao Q, Von Moltke LL, Greenblatt DJ, Court MH.

Drug Metab Dispos. 2004 Aug;32(8):862-9.

PMID:
15258112
44.

Interaction of triazolam and ketoconazole in P-glycoprotein-deficient mice.

von Moltke LL, Granda BW, Grassi JM, Perloff MD, Vishnuvardhan D, Greenblatt DJ.

Drug Metab Dispos. 2004 Aug;32(8):800-4.

PMID:
15258104
45.

Levothyroxine up-regulates P-glycoprotein independent of the pregnane X receptor.

Mitin T, Von Moltke LL, Court MH, Greenblatt DJ.

Drug Metab Dispos. 2004 Aug;32(8):779-82.

PMID:
15258100
46.

Phenacetin and chlorzoxazone biotransformation in aging male Fischer 344 rats.

Warrington JS, Court MH, Greenblatt DJ, von Moltke LL.

J Pharm Pharmacol. 2004 Jun;56(6):819-25.

PMID:
15231049
47.

Analysis of generic antiretroviral formulations manufactured in India.

Ramachandran G, Perloff ES, von Moltke LL, Swaminathan S, Wanke CA, Greenblatt DJ.

AIDS. 2004 Jul 2;18(10):1482-4. No abstract available.

PMID:
15199331
48.

Pharmacogenetic determinants of interindividual variability in bupropion hydroxylation by cytochrome P450 2B6 in human liver microsomes.

Hesse LM, He P, Krishnaswamy S, Hao Q, Hogan K, von Moltke LL, Greenblatt DJ, Court MH.

Pharmacogenetics. 2004 Apr;14(4):225-38. Erratum in: Pharmacogenetics. 2005 Apr;15(4):265.

PMID:
15083067
49.

UDP-glucuronosyltransferase (UGT) 2B15 pharmacogenetics: UGT2B15 D85Y genotype and gender are major determinants of oxazepam glucuronidation by human liver.

Court MH, Hao Q, Krishnaswamy S, Bekaii-Saab T, Al-Rohaimi A, von Moltke LL, Greenblatt DJ.

J Pharmacol Exp Ther. 2004 Aug;310(2):656-65. Epub 2004 Mar 25.

PMID:
15044558
50.

Ritonavir and dexamethasone induce expression of CYP3A and P-glycoprotein in rats.

Perloff MD, von Moltke LL, Greenblatt DJ.

Xenobiotica. 2004 Feb;34(2):133-50.

PMID:
14985144

Supplemental Content

Loading ...
Support Center